How to Help Your Patients Find Adefovir in Stock: A Provider's Guide

If you have patients on adefovir dipivoxil (Hepsera) for chronic hepatitis B, you have likely received calls about difficulty filling the prescription. Because adefovir is a lower-volume specialty medication, retail pharmacies often do not keep it in stock. This guide gives you practical, actionable strategies to help patients get their medication without requiring significant time from your clinical staff.

Why Your Patients Are Having Trouble Filling Adefovir

Adefovir's clinical use has declined as newer, more potent antivirals (entecavir, TDF, TAF) have become the standard of care for hepatitis B. As a result, pharmacies stock it less frequently. Patients report calling 5-10 pharmacies before finding one with adefovir in stock. This is not a declared shortage — it is a stocking issue driven by low local demand. As of 2026, adefovir is not on the FDA Drug Shortage List, but that provides little comfort to a patient who cannot get their refill.

Tool 1: Refer Patients to medfinder

medfinder is a paid service designed specifically for situations like this. When a patient enters their medication, strength, and ZIP code, medfinder calls pharmacies near them to find which ones can fill the prescription today. Results are sent via text. This removes the burden from both the patient and your care team. Learn more at medfinder.com/providers.

You can include medfinder in your discharge instructions, patient portal messaging, or as a standing recommendation for any patient who reports difficulty finding adefovir. A simple line in your after-visit summary — "If you have trouble filling this prescription, try medfinder.com" — can save significant frustration.

Tool 2: Route Prescriptions to Specialty or Mail-Order Pharmacies

Retail pharmacies are not always the best option for adefovir. Consider these alternatives for stable, long-term patients:

Mail-order pharmacies (PBM-affiliated): Express Scripts, CVS Caremark, and Optum Rx handle a wide formulary including adefovir and can dispense 90-day supplies. For patients on chronic hepatitis B therapy, this eliminates monthly refill stress.

Specialty pharmacies: Hepatology-focused specialty pharmacies are familiar with low-volume antivirals and can often source adefovir reliably. Ask your local hospital system if they have a preferred specialty pharmacy for hepatitis B patients.

Cost Plus Drugs (Mark Cuban): Offers adefovir dipivoxil at significantly reduced prices and ships to most states. This can be a good option for uninsured or underinsured patients.

Tool 3: Authorize Early Refills Proactively

Many patients run into trouble because they wait until the last day of their supply to seek a refill, only to find adefovir unavailable. Build an early-refill buffer into your prescribing practice:

Authorize refills with 5-7 days' overlap allowed

Document the availability issue in the chart to support insurance override if needed

Encourage patients to call for a refill when 10 days of supply remain, not 1-2 days

39,333+ patients found their medications in stock

39K+

Find Adefovir In Stock Today →

Patient Script: What to Tell Patients About Finding Adefovir

Here is suggested language you or your staff can use when a patient calls about adefovir being out of stock:

"Adefovir is not in shortage, but it is a lower-volume medication that some pharmacies do not stock. Here is what to do: Try medfinder.com — they will call pharmacies near you to find one that has it today. You can also ask your current pharmacy to order it, which usually takes 1-2 days. Do not stop taking adefovir without calling us first, because stopping suddenly can cause a serious hepatitis B flare. Call us back if you cannot find it in the next 24 hours."

When to Consider Switching a Patient Off Adefovir

If a patient is repeatedly unable to find adefovir or is becoming non-adherent due to supply difficulties, a clinically appropriate switch to a first-line agent (entecavir, TDF, or TAF) may be the best long-term solution. Key clinical considerations before switching:

Review resistance history — especially lamivudine exposure and prior virologic breakthroughs

Check current renal function before initiating TDF (preferred: eGFR > 50 mL/min; use TAF if renal impairment present)

Do NOT overlap adefovir and tenofovir (TDF or TAF) — contraindicated due to additive nephrotoxicity

Monitor liver enzymes and HBV DNA at 4-12 weeks post-switch to confirm maintained viral suppression

For a deeper clinical review, see: Adefovir Shortage: What Providers and Prescribers Need to Know in 2026